A Study of ASP2138 Given Before Surgery, Then Chemotherapy After Surgery, in People With Pancreatic Ductal Cancer
- Conditions
- Pancreatic Ductal Adenocarcinoma
- Interventions
- First Posted Date
- 2025-06-17
- Last Posted Date
- 2025-06-17
- Lead Sponsor
- Astellas Pharma Global Development, Inc.
- Target Recruit Count
- 25
- Registration Number
- NCT07024615
A Phase 2 Study to Evaluate the Effects of ASP5541 in Participants With Prostate Cancer
- Conditions
- Prostate CancerMetastatic Castration-Resistant Prostate CancerMetastatic Hormone Sensitive Prostate Cancer
- Interventions
- First Posted Date
- 2025-06-05
- Last Posted Date
- 2025-06-05
- Lead Sponsor
- Astellas Pharma Global Development, Inc.
- Target Recruit Count
- 218
- Registration Number
- NCT07005154
A Study of Zolbetuximab Together With Pembrolizumab and Chemotherapy in Adults With Gastric Cancer
- Conditions
- Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or CancerLocally Advanced Unresectable Gastric Adenocarcinoma or CancerMetastatic Gastric Adenocarcinoma or CancerMetastatic Gastroesophageal Junction (GEJ) Adenocarcinoma
- Interventions
- Drug: Folinic acid (leucovorin or local equivalent)Drug: Placebo
- First Posted Date
- 2025-03-30
- Last Posted Date
- 2025-06-18
- Lead Sponsor
- Astellas Pharma Global Development, Inc.
- Target Recruit Count
- 500
- Registration Number
- NCT06901531
- Locations
- 🇯🇵
National Cancer Center Hospital East, Kashiwa, Chiba, Japan
A Safety Study of Enfortumab Vedotin in Indian Adults With Urothelial Cancer
- Conditions
- Metastatic Urothelial Carcinoma
- Interventions
- Drug: Enfortumab Vedotin
- First Posted Date
- 2025-03-06
- Last Posted Date
- 2025-03-06
- Lead Sponsor
- Astellas Pharma Global Development, Inc.
- Target Recruit Count
- 100
- Registration Number
- NCT06862219
A Study to Confirm if Fezolinetant Helps Reduce Hot Flashes in Chinese Women Going Through Menopause
- First Posted Date
- 2025-02-06
- Last Posted Date
- 2025-06-29
- Lead Sponsor
- Astellas Pharma Global Development, Inc.
- Target Recruit Count
- 150
- Registration Number
- NCT06812754
- Locations
- 🇨🇳
Zhujiang Hospital of Southern Medical University, Guangzhou, Guangdong, China
🇨🇳Beijing Hospital, Beijing, Beijing, China
🇨🇳Capital Medical University (CMU) - Beijing Shijitan Hospital, Beijing, Beijing, China
A Study to Learn How Avacincaptad Pegol (Izervay™) is Used in Clinical Practice in People Who Have Geographic Atrophy
- Conditions
- Geographic AtrophyMacular Degeneration
- Interventions
- Drug: Avacincaptad pegol (ACP)
- First Posted Date
- 2025-01-17
- Last Posted Date
- 2025-06-27
- Lead Sponsor
- Astellas Pharma Global Development, Inc.
- Target Recruit Count
- 1000
- Registration Number
- NCT06779773
- Locations
- 🇺🇸
Retinal Consultants Medical Group Inc, Sacramento, California, United States
🇺🇸Colorado Retina Associates, PLLC, Lakewood, Colorado, United States
🇺🇸Illinois Retina Associates, Oak Park, Illinois, United States
A Study of ASP1893 in Adults With Advanced CLDN6-positive Solid Tumors
- Conditions
- Testicular CancerCLDN6-positive Solid TumorOvarian CancerEndometrial CancerMetastatic or Locally Advanced Solid Tumor CancerNon-small Cell Lung Cancer
- Interventions
- First Posted Date
- 2024-11-08
- Last Posted Date
- 2025-01-15
- Lead Sponsor
- Astellas Pharma Global Development, Inc.
- Target Recruit Count
- 197
- Registration Number
- NCT06681870
A Study to Evaluate the Effects of ASP5502 in Healthy Adults and Adults With Primary Sjögren's Syndrome
- Conditions
- Healthy VolunteersSjögren's Syndrome
- Interventions
- Drug: Placebo
- First Posted Date
- 2024-08-09
- Last Posted Date
- 2025-05-08
- Lead Sponsor
- Astellas Pharma Global Development, Inc.
- Target Recruit Count
- 132
- Registration Number
- NCT06544642
- Locations
- 🇺🇸
Fortrea Clinical Research Unit Inc, Daytona Beach, Florida, United States
Experiment to Assess Preferences for Novel Hormonal Therapy and Androgen-deprivation Therapy in Prostate Cancer Patients
- Conditions
- Prostate Cancer
- Interventions
- Other: No Intervention
- First Posted Date
- 2024-07-15
- Last Posted Date
- 2025-05-06
- Lead Sponsor
- Astellas Pharma Global Development, Inc.
- Target Recruit Count
- 374
- Registration Number
- NCT06500741
- Locations
- 🇺🇸
Analysis Group, Inc., Boston, Massachusetts, United States
A Study to Confirm if Fezolinetant Helps Reduce Hot Flashes in Women With Breast Cancer Who Are Having Hormone Therapy
- Conditions
- Hot Flashes
- Interventions
- First Posted Date
- 2024-06-04
- Last Posted Date
- 2025-06-29
- Lead Sponsor
- Astellas Pharma Global Development, Inc.
- Target Recruit Count
- 540
- Registration Number
- NCT06440967
- Locations
- 🇨🇦
Site CA15002, Montreal, Quebec, Canada
🇨🇦Site CA15001, Quebec City, Quebec, Canada
🇨🇦Site CA15003, Sherbrooke, Quebec, Canada